{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T12:52:11Z","timestamp":1769345531254,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Akita University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Bosutinib is known to increase serum creatinine levels, and its mechanism of action is believed to involve a decrease in tubular creatinine excretion due to inhibition of tubular transporters and organic cation transporter 2. This study aimed to determine whether discontinuation of bosutinib could reverse bosutinib-induced elevation of serum creatinine levels. Serum creatinine levels were compared immediately before and after bosutinib administration and after bosutinib discontinuation in 11 patients with chronic myeloid leukemia. The median serum creatinine concentration significantly increased from 0.66\u00a0mg\/dL before bosutinib to 0.76\u00a0mg\/dL after bosutinib (<jats:italic>P<\/jats:italic>\u2009=\u20090.003) and decreased from 0.79\u00a0mg\/dL before discontinuation of bosutinib to 0.66\u00a0mg\/dL after discontinuation of bosutinib at 3\u00a0months (<jats:italic>P<\/jats:italic>\u2009=\u20090.005). This study revealed that bosutinib-induced elevation of serum creatinine, which was more pronounced in patients with the <jats:italic>SLC22A2<\/jats:italic> 808G\/G genotype, does not indicate chronic kidney disease, but rather is simply a laboratory abnormality. If bosutinib-induced chronic kidney disease is suspected, renal function should be assessed by urinalysis and cystatin C levels to differentiate from simple elevation of serum creatinine.<\/jats:p>","DOI":"10.1007\/s12185-025-03954-w","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T17:41:59Z","timestamp":1740505319000},"page":"66-72","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Stopping bosutinib reverses bosutinib-induced elevation of serum creatinine in patients with chronic myeloid leukemia"],"prefix":"10.1007","volume":"122","author":[{"given":"Maiko","family":"Abumiya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayano","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Fujioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatomo","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6758-3787","authenticated-orcid":false,"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"3954_CR1","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1002\/cncr.29587","volume":"121","author":"M Yilmaz","year":"2015","unstructured":"Yilmaz M, Lahoti A, O\u2019Brien S, Nogueras-Gonz\u00e1lez GM, Burger J, Ferrajoli A, et al. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer. 2015;121:3894\u2013904. https:\/\/doi.org\/10.1002\/cncr.29587.","journal-title":"Cancer"},{"key":"3954_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15072041","author":"M Cellier","year":"2023","unstructured":"Cellier M, Bourneau-Martin D, Abbara C, Crosnier A, Lagarce L, Garnier AS, et al. Renal safety profile of BCR-ABL tyrosine kinase inhibitors in a real-life setting: A study based on Vigibase\u00ae, the WHO pharmacovigilance database. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15072041.","journal-title":"Cancers (Basel)."},{"key":"3954_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-024-03865-2","author":"N Takahashi","year":"2024","unstructured":"Takahashi N, Takenaka K, Iriyama N, Kirito K, Kawaguchi T, Kimura S, et al. JSH practical guidelines for hematological malignancies, 2023: leukemia-4. Chronic myeloid leukemia (CML)\/myeloproliferative neoplasms (MPN). Int J Hematol. 2024. https:\/\/doi.org\/10.1007\/s12185-024-03865-2.","journal-title":"Int J Hematol"},{"key":"3954_CR4","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","volume":"2","author":"J Douxfils","year":"2016","unstructured":"Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogn\u00e9 JM. Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis. JAMA Oncol. 2016;2:625\u201332. https:\/\/doi.org\/10.1001\/jamaoncol.2015.5932.","journal-title":"JAMA Oncol"},{"key":"3954_CR5","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","volume":"118","author":"JE Cortes","year":"2011","unstructured":"Cortes JE, Kantarjian HM, Br\u00fcmmendorf TH, Kim DW, Turkina AG, Shen ZX, et al. Safety and efficacy of Bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118:4567\u201376. https:\/\/doi.org\/10.1182\/blood-2011-05-355594.","journal-title":"Blood"},{"key":"3954_CR6","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","volume":"30","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kim DW, Kantarjian HM, Br\u00fcmmendorf TH, Dyagil I, Griskevicius L, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30:3486\u201392. https:\/\/doi.org\/10.1200\/JCO.2011.38.7522.","journal-title":"J Clin Oncol"},{"key":"3954_CR7","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.clml.2017.06.001","volume":"17","author":"JE Cortes","year":"2017","unstructured":"Cortes JE, Gambacorti-Passerini C, Kim DW, Kantarjian HM, Lipton JH, Lahoti A, et al. Effects of Bosutinib treatment on renal function in patients with Philadelphia chromosome-positive leukemias. Clin Lymphoma Myeloma Leuk. 2017;17:684-695.e6. https:\/\/doi.org\/10.1016\/j.clml.2017.06.001.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3954_CR8","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","volume":"36","author":"TH Br\u00fcmmendorf","year":"2022","unstructured":"Br\u00fcmmendorf TH, Cortes JE, Milojkovic D, Gambacorti-Passerini C, Clark RE, le Coutre P, et al. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022;36:1825\u201333. https:\/\/doi.org\/10.1038\/s41375-022-01589-y.","journal-title":"Leukemia"},{"key":"3954_CR9","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s12185-022-03435-4","volume":"116","author":"T Ono","year":"2022","unstructured":"Ono T, Hino M, Matsumura I, Fujisawa S, Ishizawa K, Sakaida E, et al. Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study. Int J Hematol. 2022;116:871\u201382. https:\/\/doi.org\/10.1007\/s12185-022-03435-4.","journal-title":"Int J Hematol"},{"key":"3954_CR10","doi-asserted-by":"publisher","first-page":"6362","DOI":"10.1038\/s41598-021-85757-7","volume":"11","author":"M Abumiya","year":"2021","unstructured":"Abumiya M, Takahashi N, Takahashi S, Yoshioka T, Kameoka Y, Miura M. Effects of SLC22A2 808G>T polymorphism and Bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving Bosutinib therapy. Sci Rep. 2021;11:6362. https:\/\/doi.org\/10.1038\/s41598-021-85757-7.","journal-title":"Sci Rep"},{"key":"3954_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40164-018-0101-1","volume":"7","author":"A Mita","year":"2018","unstructured":"Mita A, Abumiya M, Miura M, Niioka T, Takahashi S, Yoshioka T, et al. Correlation of plasma concentration and adverse effects of Bosutinib: standard dose or dose-escalation regimens of Bosutinib treatment for patients with chronic myeloid leukemia. Exp Hematol Oncol. 2018;7:9. https:\/\/doi.org\/10.1186\/s40164-018-0101-1.","journal-title":"Exp Hematol Oncol"},{"key":"3954_CR12","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/FPC.0b013e328302cd41","volume":"18","author":"ZJ Wang","year":"2008","unstructured":"Wang ZJ, Yin OQ, Tomlinson B, Chow MS. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics. 2008;18:637\u201345. https:\/\/doi.org\/10.1097\/FPC.0b013e328302cd41.","journal-title":"Pharmacogenet Genomics"},{"key":"3954_CR13","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1023\/b:pham.0000029286.45788.ad","volume":"21","author":"Y Urakami","year":"2004","unstructured":"Urakami Y, Kimura N, Okuda M, Inui K. Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm Res. 2004;21:976\u201381. https:\/\/doi.org\/10.1023\/b:pham.0000029286.45788.ad.","journal-title":"Pharm Res"},{"key":"3954_CR14","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/clpt.2009.139","volume":"86","author":"KK Filipski","year":"2009","unstructured":"Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther. 2009;86:396\u2013402. https:\/\/doi.org\/10.1038\/clpt.2009.139.","journal-title":"Clin Pharmacol Ther"},{"key":"3954_CR15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/clpt.2008.61","volume":"84","author":"IS Song","year":"2008","unstructured":"Song IS, Shin HJ, Shim EJ, Jung IS, Kim WY, Shon JH, et al. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther. 2008;84:559\u201362. https:\/\/doi.org\/10.1038\/clpt.2008.61.","journal-title":"Clin Pharmacol Ther"},{"key":"3954_CR16","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s10157-012-0638-y","volume":"16","author":"K Iwata","year":"2012","unstructured":"Iwata K, Aizawa K, Kamitsu S, Jingami S, Fukunaga E, Yoshida M, et al. Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events. Clin Exp Nephrol. 2012;16:843\u201351. https:\/\/doi.org\/10.1007\/s10157-012-0638-y.","journal-title":"Clin Exp Nephrol"},{"key":"3954_CR17","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/jcpt.12097","volume":"38","author":"Y Hinai","year":"2013","unstructured":"Hinai Y, Motoyama S, Niioka T, Miura M. Absence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies. J Clin Pharm Ther. 2013;38:498\u2013503. https:\/\/doi.org\/10.1111\/jcpt.12097.","journal-title":"J Clin Pharm Ther"},{"key":"3954_CR18","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/ki.2014.66","volume":"86","author":"EI Lepist","year":"2014","unstructured":"Lepist EI, Zhang X, Hao J, Huang J, Kosaka A, Birkus G, et al. Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat. Kidney Int. 2014;86:350\u20137. https:\/\/doi.org\/10.1038\/ki.2014.66.","journal-title":"Kidney Int"},{"key":"3954_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12185-020-02880-3","volume":"112","author":"S Okamoto","year":"2020","unstructured":"Okamoto S, Ureshino H, Kawaguchi A, Miyazono M, Ikeda Y, Kimura S. Assessment of estimated glomerular filtration rate in patients with chronic myeloid leukemia following discontinuation of tyrosine kinase inhibitors. Int J Hematol. 2020;112:41\u20135. https:\/\/doi.org\/10.1007\/s12185-020-02880-3.","journal-title":"Int J Hematol"},{"key":"3954_CR20","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851\u20137. https:\/\/doi.org\/10.1200\/JCO.2015.66.2866.","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03954-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-03954-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03954-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T11:17:30Z","timestamp":1750936650000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-03954-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3954"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-03954-w","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"14 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Naoto Takahashi reports receiving speaker fees from Novartis Pharmaceuticals and Pfizer, grants and speaker fees from Otsuka Pharmaceutical, and grants from Asahi Kasei Pharma, outside of the submitted work. The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}